ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CARL vs NPCE // FORWARD P/E MULTIPLE

Carlsmed Inc. (NASDAQ) VS. Neuropace Inc. (NASDAQ) • 15-METRIC TALLY: CARL 2 — NPCE 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CARL VS. NPCE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CARL NPCE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 75.30% 77.20% -1.90 NPCE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -23.00% -12.00 NPCE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.88% -2.54% -4.34 NPCE /fcf-yield <GO>
Operating Margin -60.00% -16.30% -43.70 NPCE /operating-margins <GO>
Net Profit Margin -58.70% -21.50% -37.20 NPCE /net-margins <GO>
Revenue Growth (YoY) — 25.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 7.83 0.20 +7.63 CARL /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 NPCE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 59.5 48.7 +10.80 CARL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $430.6M $446.6M -$16.0M NPCE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CARL REV NPCE REV CARL GROSS % NPCE GROSS % CARL FCF NPCE FCF
FY 2025 $50.5M $100.0M 75.3% 77.2% -$29.6M -$11.3M
FY 2024 $27.2M $79.9M 73.8% 73.9% -$25.6M -$18.3M
FY 2023 — $65.4M — — — -$19.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CARL // BETA —
NPCE // BETA —